Literature DB >> 4328085

Myasthenia gravis, ulcerative colitis and lichen planus.

T N Miller.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 4328085      PMCID: PMC1811999     

Source DB:  PubMed          Journal:  Proc R Soc Med        ISSN: 0035-9157


× No keyword cloud information.
  10 in total

1.  SYSTEMIC LUPUS ERYTHEMATOSUS, CIRRHOSIS AND ULCERATIVE COLITIS AFTER THYMECTOMY FOR MYASTHENIA GRAVIS.

Authors:  R F GALBRAITH; W H SUMMERSKILL; J MURRAY
Journal:  N Engl J Med       Date:  1964-01-30       Impact factor: 91.245

2.  SYSTEMIC LUPUS ERYTHEMATOSUS FOLLOWING THYMECTOMY FOR MYSTHENIA GRAVIS. REPORT OF TWO CASES.

Authors:  D ALARCON SEGOVIA; R F GALBRAITH; J E MALDONADO; F M HOWARD
Journal:  Lancet       Date:  1963-09-28       Impact factor: 79.321

3.  PREDNISONE AS MAINTENANCE TREATMENT FOR ULCERATIVE COLITIS IN REMISSION.

Authors:  J E LENNARD-JONES; J J MISIEWICZ; A M CONNELL; J H BARON; F A JONES
Journal:  Lancet       Date:  1965-01-23       Impact factor: 79.321

4.  Cortisone and corticotrophin in ulcerative colitis.

Authors:  S C TRUELOVE; L J WITTS
Journal:  Br Med J       Date:  1959-02-14

5.  EFFECTS OF ADRENOCORTICOTROPHIC HORMONE ON NEURO-MUSCULAR FUNCTION IN PATIENTS WITH MYASTHENIA GRAVIS.

Authors:  C Torda; H G Wolff
Journal:  J Clin Invest       Date:  1949-09       Impact factor: 14.808

6.  An unusual variant of lupus erythematosus or lichen planus.

Authors:  P W Copeman; A L Schroeter; R R Kierland
Journal:  Br J Dermatol       Date:  1970-08       Impact factor: 9.302

7.  Autoimmunity in concurrent myasthenia gravis and pemphigus erythematosus.

Authors:  E H Beutner; T P Chorzelski; W L Hale; I Hausmanowa-Petrusewicz
Journal:  JAMA       Date:  1968-03-04       Impact factor: 56.272

8.  Alternate-dy prednisone in a patient with myasthenia gravis.

Authors:  J R Warmolts; W K Engel; J N Whitaker
Journal:  Lancet       Date:  1970-12-05       Impact factor: 79.321

9.  Treatment of myasthenia gravis with adrenocorticotropic hormone (ACTH): massive short-term and maintenance treatment.

Authors:  C A Cape; R A Utterback
Journal:  J Neurol Neurosurg Psychiatry       Date:  1969-08       Impact factor: 10.154

10.  Treatment of ocular myasthenia with corticotrophin.

Authors:  F B Gibberd; F Navab; C L Smith
Journal:  J Neurol Neurosurg Psychiatry       Date:  1971-02       Impact factor: 10.154

  10 in total
  4 in total

Review 1.  Ocular myasthenia gravis and inflammatory bowel disease: a case report and literature review.

Authors:  R Foroozan; R Sambursky
Journal:  Br J Ophthalmol       Date:  2003-09       Impact factor: 4.638

2.  Ulcerative colitis, myasthenia gravis, atypical lichen planus, alopecia areata, vitiligo.

Authors:  R S Tan
Journal:  Proc R Soc Med       Date:  1974-03

3.  Associated thyreoiditis, myasthenia gravis, thymectomy, Chron's disease, and erythema nodosum: pathogenetic and clinical correlations, immune system involvement, and systemic infectious complications.

Authors:  Roberto Manfredi; Giovanni Fasulo; Ciro Fulgaro; Sergio Sabbatani
Journal:  Rheumatol Int       Date:  2008-04-04       Impact factor: 2.631

Review 4.  Cutaneous and mucosal lichen planus: a comprehensive review of clinical subtypes, risk factors, diagnosis, and prognosis.

Authors:  Farzam Gorouhi; Parastoo Davari; Nasim Fazel
Journal:  ScientificWorldJournal       Date:  2014-01-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.